Petaling Jaya: Tekchem Resources, a Malaysian conglomerate listed on major markets, has established a joint venture (JV) with Cellsource to introduce Cellsource’s Platelet Derived Factor Concentrate Freeze-Drying (PFC-FDTM) processing service signed a letter of intent to the effect that Patented in Malaysia and Japan and provided to Malaysian medical institutions.
CellSource is a regenerative medicine specialist company listed on the Tokyo Stock Exchange growth market. Headquartered in Tokyo, the company provides state-of-the-art processing services for platelet-rich plasma (PRP) derived from patient blood.
CellSource uses an innovative, patented process to concentrate the growth factors present in PRP to create PFC-FDTM. This patented and innovative process allows PFC-FDTM to be stored at room temperature for long periods of time, ensuring long-term viability and potency.
CellSource’s PFC-FDTM processing services will be available in Malaysia subject to approval by the Malaysian National Drugs Regulatory Agency.
Masato Tsumamoto, CEO and Representative Director of CellSource Co Ltd. Malaysia was our first destination and was chosen due to its medical tourism potential enhanced by the establishment and support of the Malaysian Healthcare Travel Council.
“Therefore, we are delighted to have Texchem as our partner in taking advantage of these enormous opportunities together. More importantly, we are leveraging our collective expertise and resources to We are committed to delivering breakthrough regenerative solutions that positively impact outcomes and advance the regenerative medicine sector in Malaysia and beyond.”
Fumihiko Tan Sri Konishi, Executive Chairman of Texchem Resources Group, said: “As an innovator in the field of regenerative medicine, he is very excited to partner with CellSource and believes there will be strong synergies from this partnership.”
“Our in-house team has a proven track record of serving the medical/life sciences sector and has achieved multiple accreditations that further validate our expertise and commitment to excellence. We have partnered with and are well positioned to introduce their innovative and patented PFC-FDTM treatment services across Malaysia and to other healthcare facilities.
“By combining our expertise and resources, we aim to bring state-of-the-art regenerative solutions to the medical practice of this country.
“Further adding to our excitement is the honor of being CellSource’s first overseas partner, which demonstrates CellSource’s confidence in our capabilities.”
Penang-based Texhem and Cellsource plan to set up a joint venture in Malaysia by the end of the year.
